Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy TranscriptSeeking Alpha · Oct 7, 2026
Capricor Highlights Two-Year Deramiocel Data as FDA Decision NearsMarketBeat · Oct 7, 2026
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society CongressGlobeNewsWire · Oct 5, 2026
Inflation Breather Could Help Stocks Finish Q3 StrongSchaeffers Research · Sep 30, 2026
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026Business Wire · Sep 28, 2026
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPRGlobeNewsWire · Sep 28, 2026Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.59 | -$0.70 | Miss |
| May 12, 2026 | -$0.55 | -$0.59 | Miss |
| Mar 12, 2026 | -$0.51 | -$0.62 | Miss |
| Nov 10, 2025 | -$0.54 | -$0.54 | Beat |
| Aug 11, 2025 | -$0.48 | -$0.57 | Miss |
| May 13, 2025 | -$0.33 | -$0.53 | Miss |